Antares Pharma Inc

Antares Pharma — Jefferies 2016 Healthcare Conference

22 slides from Antares Pharma's conference presentation, Jun 8, 2016

  1. Slide 1: Jefferies 2016 Healthcare Conference

    NASDAQ: ATRS Jefferies 2016 Healthcare Conference June 8, 2016 Robert F. Apple President and Chief Executive Officer Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate

  3. Slide 3: Antares Pharma

    Antares Pharma A Growing, Revenue Generating State-of-the-Art Specialty Pharmaceutical Company An Innovative Leader In Self-Administered Injection Technology Four Drug/Drug-Device Products FDA Approved Since 2012 (most recently Sumatriptan and OTREXUP™) Two Additional Drug Device Combination Product

  4. Slide 4: Top Line Highlights

    Top Line Highlights Q116 total revenue of $12.3 million vs. $8.3 million in Q115 – a 48% increase vs. the comparable period Multiple development pipeline products targeting therapeutic markets with ~ $8 Billion in annual revenue over next five years Recently announced last patient visit in QST 15-00

  5. Slide 5: Diverse Pipeline of Proprietary and Partnered Products

    Diverse Pipeline of Proprietary and Partnered Products Product Overview Product Brand/Partner Device Drug Indications Development/ Approval Status Financial Consideration OTREXUP™ Vibex Methotrexate (MTX) RA; pJIA Psoriasis US launch 2014 Proprietary Product Sales Launched with in-house sales force

  6. Slide 6: 2016 Potential Value Drivers

    2016 Potential Value Drivers Sumatriptan mid-year launch by Teva Anticipate QuickShot® Testosterone NDA filing late 2016 Alliance Business progress: Makena® life cycle management collaboration with AMAG Growth of OTREXUP™ Continued progress on pipeline (Epinephrine, Exenatide, Teriparatide)

  7. Slide 7: Value Driver #1 – VIBEX Sumatriptan Launch

    Value Driver #1 – VIBEX® Sumatriptan Launch December 15, 2015 FDA approval; expected mid-year 2016 launch by Teva Therapeutically Equivalent to Imitrex® STATdose addressing a $200 million retail injectable market 50/50 profit split with Teva Antares produces final product & sells to Teva at cost Tev

  8. Slide 8: Injectable Sumatriptan Market Opportunity

    Injectable Sumatriptan Market Opportunity Source: Symphony Health Solutions 2015 Retail PHAST Legacy 2.0 TRx Dollars, Auto/Pen Injector Market ~ $200 Million

  9. Slide 9: Value Driver #2 – NDA Filing For QuickShot Testosterone

    Value Driver #2 – NDA Filing For QuickShot® Testosterone NDA filing currently targeted for late Q416 Possible launch in late 2017 / early 2018 Final safety data from 52 week 003 study reported – most common included increased hematocrit, hypertension, upper respiratory tract infection, sinusitis, in

  10. Slide 10: Testosterone Replacement Therapy Market 2011-2015

    Testosterone Replacement Therapy Market 2011-2015 Source: Symphony Health Solutions 2015 Retail Value of TRT Market - $2.8 Billion 2015 Monthly TRx appear to be Stabilizing

  11. Slide 11: QST-13-003 Exceeded all Protocol-Required Outcomes

    QST-13-003 Exceeded all Protocol-Required Outcomes1 Population/Analysis Cavg Lower limit of the 95% 2-sided C. I. C avg % in Range 300 – 1100 ng/dL n (%) Cmax <1500 ng/dL n (%) Cmax >1800 ng/dL n (%) Primary analysis* N=150 87.3% 139 (92.7%) 137 (91.3%)** 0% Completers N=137 94.8% 135 (98.5%) 137 (1

  12. Slide 12: Value Driver #3 – Grow Alliance Business

    Value Driver #3 – Grow Alliance Business AMAG Makena® alliance (began in 2014) Developing a subcutaneous auto injector device Better patient compliance Potentially less painful injection (small gauge needle) and easier administration Currently Makena® is ~ $250 million product opportunity, expected

  13. Slide 13: Makena Life Cycle Program

    Makena® Life Cycle Program Preservative free More convenient for HCPs More cost effective for insurers Approved 2/23/16, launched 4/4/16 Device partner Antares Issued & pending patents Potential for less painful injections sNDA estimated filing in 2Q17 with 6 month regulatory review Makena® subcutan

  14. Slide 14: Value Driver #4 – OTREXUP Growth

    Value Driver #4 – OTREXUP™ Growth First approved methotrexate for subcutaneous injection in the U.S. Single-use, disposable & easy to use Collar activated, no push button, easy to grip and virtually painless Needle guard prevents accidental sticks Audible click followed by red indicator to confirm i

  15. Slide 15: OTREXUP

    OTREXUP™ Q116 Revenues of $3.3 million are up 10% vs. Q115; flat vs Q4 2015 Committed to growing OTREXUP™: Changes in leadership of both sales and marketing organizations Modifying certain payer tactics Take advantage of new interim dosage strengths that have recently been launched

  16. Slide 16: Near Term Pipeline Opportunities

    Near Term Pipeline Opportunities Epinephrine Auto Injector Exenatide Teriparatide

  17. Slide 17: VIBEX Epinephrine Auto Injector

    VIBEX® Epinephrine Auto Injector Teva filed ANDA amendment with FDA in December 2014, Complete Response Letter (CRL) issued February 2016, Teva and Antares working together to answer FDA questions 2015 EpiPen® retail sales were $2.2 billion per Symphony Health Solutions Shipped $6.0 million in devic

  18. Slide 18: Exenatide

    Exenatide Teva submitted ANDA to FDA 10/14 – accepted 12/14 AstraZeneca and Amylin filed lawsuit in response to Teva’s Paragraph IV notice 12/14 – 30 month clock to mid-2017 Based on available information, Antares believes Teva has first to file status According to Symphony Health Solutions retail P

  19. Slide 19: Teriparatide

    Teriparatide Teva submitted ANDA to FDA – accepted 2/16 Eli Lilly filed a lawsuit on 3/16/16 in response to Teva’s Paragraph IV notice, 30 month clock to Q318 Based upon available information, Antares believes Teva may have first to file status and may be entitled to 180 days of generic exclusivity

  20. Slide 20: First Quarter 2016 Financial Results

    First Quarter 2016 Financial Results Three Months Ended Mar 31 Increase 2016 2015 (Decrease) Total Revenue $ 12,319 $ 8,348 48% Cost of Revenue 6,776 3,675 84% Gross Profit 5,543 4,673 19% % Revenues 45% 56% Research & Development 5,648 4,378 29% Selling, General & Administrative 7,603 7,037 8% Tota

  21. Slide 21: Investment Considerations

    Investment Considerations A growing, revenue generating company – $12.3 million in Q116 – a 48% increase over first quarter of last year Multiple development pipeline products targeting therapeutic markets with ~ $8 Billion in annual revenue over next five years Several potential value drivers in 20

  22. Slide 22: Jefferies 2016 Healthcare Conference

    NASDAQ: ATRS Jefferies 2016 Healthcare Conference June 8, 2016 Robert F. Apple President and Chief Executive Officer

Antares Pharma — Jefferies 2016 Healthcare Conference on 6ix